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To the Editor: 
We read with interest the article by Turiel et al. recently published in Arthritis Care & Research (1), 
which suggested the presence of subclinical atherosclerosis (ATS) in patients with systemic 
sclerosis (SSc), as indicated by early impairment of coronary flow reserve (CFR), increased carotid 
artery stiffness and carotid intima-media thickness (IMT), and there are some comments we would 
like to make.  
The recent interest on this topic is probably the consequence of improvement in overall survival of 
SSc patients and increase of non-SSc comorbidities which contribute to mortality (2).  
Microvascular damage is considered to be a hallmark of SSc. Nevertheless, there have been 
conflicting reports regarding the presence and extent of macrovascular disease that might evolve 
due to ATS in SSc patients (3). The microvascular changes described in SSc include endothelial 
damage and smooth muscle cell migration in the intima, which may resemble atherosclerotic 
changes. Despite conflicting results of IMT in SSc patients, the most recent and largest studies of 
SSc patients found no difference in either plaque occurrence or IMT (4,5), while the prevalence of 
coronary artery and cerebrovascular disease remains unclear (6). Akram et al. found in SSc patients 
a similar prevalence of coronary artery disease compared to general population  (based on analysis 
of 172 angiographic studies, which is the gold standard to evaluate CAD) (7).   
  Atherosclerosis and SSc seem to share some pathophysiological mechanism. Proposed mediators 
of the vasculopathy of SSc which have also be implicated in atherosclerosis include endothelial 
dysfunction, a reduced number of circulating endothelial progenitor cells, and an increased number 
of microparticles (8). Thus, a diagnostic method which might differentiate between the two process 
is of primary importance in SSc. 
In general, CFR alone cannot differentiate microcirculation dysfunction from anatomic arterial 
stenosis (9) . Therefore, the common finding of abnormal CFR in SSc patients does not necessarily 
imply atherosclerotic plaque in these asymptomatic patients. In our experience, CFR impairment 
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was not sustained by epicardial coronary stenosis, as confirmed by cardiac MDCT, but seemed 
related to microcirculation involvement in SSc patients  (10). As result, it can be concluded that 
abnormal CFR in SSc patients is most probably not caused by coronary ATS. 
The role of plasma ADMA levels in SSc should be better defined; in fact lack of any correlation 
between ADMA levels and CFR in the study by Turiel et al. seems to be related to endothelial 
dysfunction but not to impaired microcirculation, differently from other rheumatic disease in which 
ithas been proposed as a surrogate  marker of subclinical ATS (11).  
Indeed, as a single marker may not be sufficient to determine the cardiovascular risk, a combination 
of different diagnostic investigations including biomarkers and imaging modalities can be utilized. 
In conclusion, the utility of all of these  markers has not been validated in well-controlled studies in 
large cohorts of SSc patients, differently from other rheumatic disease such as systemic lupus 
erythematosus and rheumatoid arthritis in which  premature and accelerated ATS has been well 
established (12, 13). As a result, their potential clinical implications remain still unclear. 
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